| Hypertensive disease
Cleviprex vs Qbrelis
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Cleviprex vs Qbrelis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQbrelis has a higher rate of injection site reactions vs Cleviprex based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qbrelis but not Cleviprex, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cleviprex
Qbrelis
At A Glance
IV infusion
Continuous infusion
Dihydropyridine CCB
Oral
Once daily
ACE inhibitor
Indications
- Hypertensive disease
- Hypertensive disease
- Heart Failure, Systolic
- Acute myocardial infarction
Dosing
Hypertensive disease Initiate IV infusion at 1-2 mg/hour; double dose at 90-second intervals initially, then increase by less than doubling every 5-10 minutes as goal blood pressure is approached; maintenance 4-6 mg/hour; maximum 16 mg/hour (up to 32 mg/hour for severe hypertension); lipid load limit 1000 mL or an average of 21 mg/hour per 24 hours.
Hypertensive disease Adults: initial 10 mg once daily (5 mg once daily if on diuretics), titrate to 20-40 mg once daily; pediatric patients >=6 years with GFR >30 mL/min/1.73m2: initial 0.07 mg/kg (up to 5 mg) once daily, maximum 0.61 mg/kg (up to 40 mg) once daily, oral.
Heart Failure, Systolic Initial 5 mg once daily (2.5 mg once daily if hyponatremia present) with diuretics and digitalis; increase as tolerated to 40 mg once daily, oral.
Acute myocardial infarction 5 mg within 24 hours of onset, then 5 mg at 24 hours, then 10 mg once daily for at least 6 weeks; initiate at 2.5 mg once daily if systolic BP <=120 mmHg, oral.
Contraindications
- Allergy to soybeans, soy products, eggs, or egg products
- Defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis accompanied by hyperlipidemia
- Severe aortic stenosis
- History of angioedema or hypersensitivity related to previous ACE inhibitor treatment
- Hereditary or idiopathic angioedema
- Co-administration of aliskiren in patients with diabetes
- Combination with a neprilysin inhibitor (e.g., sacubitril); do not administer within 36 hours of switching to or from sacubitril/valsartan
Adverse Reactions
Most common Headache, nausea, vomiting, acute renal failure, atrial fibrillation
Serious Myocardial infarction, cardiac arrest, syncope, dyspnea
Postmarketing Increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation, reflex tachycardia
Most common (>=2%) Hypertension: headache, dizziness, cough; Heart Failure: hypotension, chest pain; Acute MI: hypotension.
Serious Bone marrow depression, hemolytic anemia, leukopenia/neutropenia, thrombocytopenia, toxic epidermal necrolysis, Stevens-Johnson syndrome, pancreatitis, hyperkalemia, renal dysfunction.
Postmarketing Hyponatremia, hypoglycemia in diabetic patients, mood alterations, mental confusion, hallucinations, psoriasis.
Pharmacology
Clevidipine is a dihydropyridine L-type calcium channel blocker that lowers blood pressure by inhibiting calcium influx in arterial smooth muscle, reducing systemic vascular resistance without affecting venous preload or cardiac filling pressure.
ACE inhibitor; lisinopril inhibits angiotensin-converting enzyme, reducing conversion of angiotensin I to angiotensin II, thereby decreasing vasopressor activity and aldosterone secretion to lower blood pressure in hypertension, heart failure, and post-myocardial infarction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cleviprex
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Qbrelis
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Cleviprex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Qbrelis
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Cleviprex
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Qbrelis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cleviprex.
No savings programs available for Qbrelis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CleviprexView full Cleviprex profile
QbrelisView full Qbrelis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.